Fig. 9
- ID
- ZDB-FIG-181002-12
- Publication
- Casar et al., 2018 - RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation
- Other Figures
- All Figure Page
- Back to All Figure Page
PTPR? is a tumor suppressor in melanoma. a Analysis of PTPR? expression in normal skin (n?=?7), benign nevi (n?=?18) and cutaneous melanoma samples (n?=?45) generated using an available gene dataset, accessed through the Oncomine® platform. ***p?<?0.001 ****p?<?0.0001 by Student's t-test. b Survival curves for melanoma patients depending on PTPR? expression levels (obtained from GEO GSE65904). c View of naevi (2/28; arrowhead, middle panel) and melanoma (2/28; arrowhead bottom panel, points to a protruding eye with a retroorbital tumor.) by 52 weeks post fertilization in ptpr? nullizygous zebrafish expressing KDELr-HV12 as a transgene. Representative pictures were taken at 8 weeks post fertilization. d Kaplan?Meier plot of tumor development in ptpr? wild-type nacre animals compared to ptprk?/? nacre animals, injected with NRAS-G12D. ****p?<?0.0001 by Mantel-Cox test. e Representative melanoma lesions (see arrowheads) in zebrafish with the indicated ptpr? genotype expressing NRAS-G12D as a transgene. See also Supplementary Fig. 8 |